Company Reports

Fresenius is a major player in healthcare, specializing in injectable therapies and hospital operations. Subsidiary Kabi is among the top injectable pharmaceutical providers globally, while the Helios division is the largest private hospital operator in Germany and Spain.

Fresenius SE reported second-quarter results with 6% organic growth and 10% group EBIT growth in constant currencies. Management raised its full-year guidance for constant-currency core EPS growth to 10%–15% from 5%–10%.

Fresenius is a major player in healthcare, specializing in injectable therapies and hospital operations. Subsidiary Kabi is among the top injectable pharmaceutical providers globally, while the Helios division is the largest private hospital operator in Germany and Spain.

Fresenius' first-quarter results included 5% organic sales growth and 6% constant-currency EBIT growth, reaching an adjusted EBIT margin of 11.8%. Management confirmed its 2026 guidance for 4%-7% organic growth and an adjusted EBIT margin of 11.5%.

Fresenius SE reported fourth-quarter 2025 organic sales growth of 7%, at the high end of its organic sales guidance, and ahead of company-compiled consensus, driven by both the Kabi and Helios segments. The EBIT increased 6% in constant currencies, in line with consensus.

Fresenius SE is a major player in healthcare, specializing in injectable therapies and hospital operations. Its subsidiary Kabi is among the top injectable pharmaceutical providers globally, while its Helios division makes it the largest private hospital operator in Germany and Spain.

Fresenius is a major player in healthcare, specializing in injectable therapies and hospital operations. Its subsidiary Kabi is among the top injectable pharmaceutical providers globally, while its Helios division makes it the largest private hospital operator in Germany and Spain.

Fresenius SE reported third-quarter results with 6% organic growth driven by both the Kabi and Helios segments. Management raised their full-year group EBIT guidance to 4%-8% from 3%-7%.

Fresenius SE reported strong second-quarter results, with organic revenue growth of 5% and 8% core EPS growth. Although revenue slightly missed consensus, core EPS exceeded expectations. Shares are up, largely unchanged at the market open.

We are transferring coverage of Fresenius SE to a new analyst. Fresenius SE operates two segments: Kabi and Helios. Kabi provides injectable therapies, including clinical nutrition, IV drugs, and infusion systems. Helios has the largest network of private hospitals and clinics in Germany and Spain.

Fresenius is a major player in two areas of healthcare: injectable therapies and hospital operations. Through its subsidiary, Kabi, the company ranks among the leading providers of injectable pharmaceuticals worldwide. Its Helios division establishes Fresenius as the largest private hospital operator in both Germany and Spain.

Fresenius reported first-quarter 2025 results, with organic revenue up 7% and EBIT up 4% year over year, both well above company-compiled consensus. Shares are trading 2% higher intraday on May 7.

Narrow-moat Fresenius SE delivered on its guidance, which was raised last quarter, closing the full-year 2024 with 8% organic revenue growth and 10% EBIT growth, while its margin expanded by 40 basis points compared with the previous year. The fourth quarter saw a boost in operating income, outpacing earlier quarters of the year. Fresenius reinstated its dividend at EUR 1 per share and announced a new dividend policy of a 30%-40% payout of core net income (excluding medical care), compared with 30% or less in 2022 and earlier. Investors reacted positively, with shares jumping 7% at market opening Feb. 25. We maintain our fair value estimate of EUR 53 per share, which we increased last quarter, and we continue to view shares as undervalued.

Narrow-moat Fresenius SE turned in strong third-quarter results helped by rising medical utilization, and management increased its 2024 outlook ranges. To account for recent cash flow generated and higher near-term expectations, we are increasing our fair value estimate to EUR 53 from EUR 50 previously, and we think this operating momentum is promising for the firm's undervalued shares.

Fresenius SE’s historical prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and inorganic means.

Narrow-moat Fresenius SE turned in strong second-quarter results and highlighted that it expects to deliver results on the top end of its profit outlook range in 2024. At first glance, we do not plan to change our EUR 50 fair value estimate on these trends, but this operating momentum appears promising for the company's undervalued shares.

Narrow-moat Fresenius SE held an investor event on its Helios caregiving segment in which it mildly raised near- and intermediate-term guidance for that segment. However, that mildly improved outlook was not material enough to change our EUR 50 fair value estimate, and shares remain significantly undervalued, in our opinion.

Narrow-moat Fresenius SE turned in strong first-quarter results and increased its 2024 outlook on strength in its Kabi injectable therapies segment. At first glance, we do not plan to change our EUR 50 fair value estimate, and shares remain undervalued.

GLP-1 drug use is increasing materially in patients with diabetes and obesity, and uncertainty around GLP-1 expansion has added risk to dialysis stocks even as pandemic challenges, including excess mortality and labor costs, are easing for the narrow moat dialysis companies we cover—Baxter, DaVita, Fresenius Medical Care, and Fresenius SE. Despite the concerns, new data rolling in on GLP-1s appears roughly in line with our view that GLP-1 expansion should not materially affect dialysis demand for at least the next decade, as mildly extended kidney disease progression to dialysis may be largely offset by cardiac and first-year survival, or "crash," benefits. Considering this roughly neutral outlook, we find the significant discounts to fair value in dialysis-related stocks compelling.

Fresenius SE’s prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and inorganic means.